Literature DB >> 17066487

Truncated midkine correlates with sensitivity to anticancer drugs and malignancy in human tumor cell line.

Natsuyo Akuzawa1, Shigenori Nobata, Takao Shinozawa.   

Abstract

Midkine (MK) is a heparin binding growth factor having functions of neurite-outgrowth, mitogenesis and tissue repair. This molecule is involved in tumor growth and metastasis. The MK molecule consists of five exons, but there is a truncated isoform, lacking exon 3. We established SW13 cells transfected with the human truncated MK cDNA. These cells were induced to undergo apoptosis by anticancer agents, cisplatin, etoposide (ETP), mitomycin C (MMC) and paclitaxel (PAX). Truncated midkine (tMK) suppressed cell death and helped the cells to be viable. When the cells were cultured on dishes coated with extracellular matrix molecules, spontaneous detachment occurred in the tMK expressing cells. Also tMK enhanced cell invasion. These results suggest that expression of tMK has cell-protective functions and plays important roles in carcinogenesis and malignancy. Furthermore, it is suggested that tMK has a greater ability of malignant transformation than full-length MK. Whether tMK is expressed or not will be useful information for improving cancer chemotherapy. Copyright (c) 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17066487     DOI: 10.1002/cbf.1376

Source DB:  PubMed          Journal:  Cell Biochem Funct        ISSN: 0263-6484            Impact factor:   3.685


  2 in total

Review 1.  Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases.

Authors:  D R Jones
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

2.  Serum midkine as a biomarker for malignancy, prognosis, and chemosensitivity in head and neck squamous cell carcinoma.

Authors:  Taku Yamashita; Hideaki Shimada; Shingo Tanaka; Koji Araki; Masayuki Tomifuji; Daisuke Mizokami; Nobuaki Tanaka; Daisuke Kamide; Yoshihiro Miyagawa; Hiroshi Suzuki; Yuya Tanaka; Akihiro Shiotani
Journal:  Cancer Med       Date:  2016-01-22       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.